Piotr Bar
Sabina Galiniak
ID
 Email src
Dorota Bartusik-Aebisher
ID
 Email src
Rafal Filip
ID
 Email src
David Aebisher
ID
 Email src
Clinical Department of Pathomorphology, Clinical Hospital No. 2, Rzeszów, Poland
Department of Biochemistry and General Chemistry Medical College of Rzeszów University, Rzeszów, Poland
Department of Biochemistry and General Chemistry, Medical College of the University of Rzeszow, University of Rzeszow, Rzeszow, Poland
Department of Gastroenterology, Institute of Medical Sciences, Medical College of Rzeszow University, Rzeszow, Poland
Department of Photomedicine and Physical Chemistry, Medical College of Rzeszów University, Rzeszów, Poland
Received: 28 August 2018 / Accepted: 10 October 2018 / Published: 30 March 2019

Abstract

Introduction. Infliximab is a monoclonal antibody that acts against tumor necrosis factor TNF-α. The drug is used in the treatment of autoimmune diseases.

Aim. This article reviewed the efficacy and safety of infliximab for the treatment in severe ulcerative colitis. This review included studies that evaluated the clinical use of infliximab.

Material and methods. This meta-analysis was performed according to systematic literature search of three major bibliographic databases (Scopus, PubMed, and Cochran).

Results. Infliximab has been approved by the US Food and Drug Administration (FDA) as a medicine to treat Leśniowski and Crohn’s disease, ulcerative colitis, psoriasis, psoriatic arthritis, ankylosing spondylitis, and rheumatoid arthritis. However, further trials are required to compare other parameters of efficacy such as the clinical response with infliximab.

Conclusion. In patients suffering from Crohn’s disease or ulcerative colitis under infliximab maintenance therapy, sustained good trough levels are associated with: better response and remission rates, more mucosal healing and less loss of response. 

 

Cite

Bar P, Galiniak S, Bartusik-Aebisher D, Filip R, Aebisher D. Infliximab in therapy of inflammatory bowels diseases. Eur J Clin Exp Med. 2019;17(1):79–82. doi: 10.15584/ejcem.2019.1.13

This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited